Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. possesses a positive outlook as its product candidate, lorundrostat, has demonstrated a significant, robust, and differentiated benefit in patients with uncontrolled and resistant hypertension, showing a placebo-adjusted blood pressure reduction exceeding 10 mmHg. The clinical advantage of lorundrostat, as highlighted in discussions with key opinion leaders (KOLs), positions the drug favorably compared to Phase 3 competitors, thereby enhancing its market potential in a critical therapeutic area. Furthermore, the company's focus on near-term FDA feedback and an anticipated New Drug Application (NDA) submission indicates strong progress toward commercialization, which bodes well for future financial performance.

Bears say

Mineralys Therapeutics Inc faces significant risks that negatively impact its financial outlook, including the potential failure of its product candidate lorundrostat to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may struggle to secure adequate capital resources necessary to support ongoing operations and the development of its programs, which presents a further challenge to its financial stability. Lastly, concerns regarding patient safety, particularly related to potassium levels and potential hyperkalemia, could impede the product's commercialization and acceptance in the market.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.